Monoclonal antibody and antiviral therapy for treatment of mild-to-moderate COVID-19 in pediatric patients
Vora, S. B.; Englund, J. A.; Trehan, I.; Waghmare, A.; Kong, A.; Adler, A.; Zerr, D. M.
Show abstract
The recent surge of SARS-CoV-2 Omicron variant (B.1.1.529) coincided with new treatment options for mild-to-moderate Covid-19 in high-risk adolescents and adults. In this report we describe patient characteristics, treatment-related process measures and outcomes associated with early Covid-19 therapy in high-risk pediatric patients.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- SARS-CoV-2 Seroepidemiology in Children and Adolescents 92%
- Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia 91%
- Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, northern Tanzania 91%
Similar papers in this journal
- Compassionate Use of REGEN-COV ® in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders 92%
- Real-World Effectiveness Of Nirmatrelvir/Ritonavir On COVID-19-Associated Hospitalization Prevention: A Population-Based Cohort Study In The Province Of Québec, Canada 91%
- Usage and awareness of antiviral medications for COVID-19 91%
Similar papers in this journal
- Clinical Testing of Pediatric Mpox Specimens: Unique Features and Challenges in a Low Prevalence Population 90%
- Clinical evaluation of the molecular-based BD SARS-CoV-2/Flu for the BD MAX™ System 89%
- Evidence of Tenofovir Resistance in Chronic Hepatitis B Virus (HBV) Infection: An Observational Case Series of South African Adults 89%
Similar papers in this journal
- A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis 92%
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 91%
- Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.